Skip to content
EmergingResearch compoundReference only

Cebaracetam

Discontinued experimental nootropic from the racetam family; its effect is unclear and there is little human data.

NootropicRacetamRacetamAcetylcholineAcetylcholineGlutamate

Pharmacology

ClassRacetam · Acetylcholine
Primary targetCholinergic transmission modulator (mechanism undefined)
Targets3 receptor targets
Half-lifeN/A
OnsetN/A
EvidenceReference only
Affected systemsAcetylcholineGlutamate

Contents

DETAILED OVERVIEW

What is Cebaracetam?

Cebaracetam is an experimental compound from the racetam family, developed by Novartis (formerly Ciba-Geigy) for cognitive disorders, meaning a decline in thinking and memory. Development reached the second stage of clinical trials and was stopped in 1995. The compound was never marketed and was never approved for any medical use.

Its mechanism was never clearly established: early research pointed to effects on signaling between nerve cells (the acetylcholine and glutamate systems) and to protection against damage from lack of oxygen, but all of this was weak. There is practically no human data; the published material is limited to a single laboratory method paper (a urine test). Its safety in humans has never been established, so it should be avoided in pregnancy and breastfeeding, and any self-experimentation is strongly contraindicated. It does not replace evidence-based treatment. The purity and identity of material sold as a research chemical are a separate, unknown risk.

Mechanism

Undefined (weak cholinergic / glutamatergic)

Half-life

N/A (not characterized)

Onset

N/A (no validated protocol)

Status

Discontinued phase II (Novartis, 1995); unapproved

Receptor profile

  • Cholinergic transmissionWeak
  • Glutamatergic (AMPA / NMDA) signalingWeak
  • Neuronal resilience under ischemiaWeak

Safety

Side effects, stop signs, contraindications

Side effects · 4

  • The human safety profile was never established; no long-term human safety data exist
  • Because development was halted at phase II, no adverse-effect frequency data were ever published
  • As with other racetams, cholinergic-type effects (such as headache) are plausible but unverified for this compound
  • The purity and identity of any grey-market or research-chemical material is a separate, uncharacterized risk

Contraindications · 4

  • Not for human consumption: an unapproved investigational compound with no established safety
  • Pregnancy and breastfeeding: no data whatsoever, must be avoided
  • Any self-experimentation is strongly discouraged given the absence of dosing, safety and interaction data
  • Not a substitute for evidence-based cognitive treatments; consult a physician for genuine cognitive concerns

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Cebaracetam is an obscure, experimental compound from the racetam family, developed by Novartis for cognitive disorders, but development was discontinued at phase II clinical trials. It was studied preclinically (in animals) for memory and learning problems and for possible neuroprotection under low-oxygen stress, but none of this was ever confirmed in humans. In practice it is mostly a historical curiosity within the racetam family, not an established or well-documented substance.

Telegram

Have a question about Cebaracetam?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC16H18ClN3O3
UpdatedOctober 14, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.